95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Urol.
Sec. Male Urology
Volume 5 - 2025 | doi: 10.3389/fruro.2025.1565240
This article is part of the Research Topic Innovations and Advancements in the Management of Male Lower Urinary Tract Symptoms (LUTS) View all articles
Comparison of Serenoa Repens, Lycopene and Selenium Versus Dutasteride for theTreatment of LUTS/BPH. An Italian Multicenter Case-Control Prospective Study.(COMP Study)
Provisionally accepted
Giuseppe Morgia 1,2*
Arturo Lo Giudice 3
Sebastiano Cimino 1 Giulio Reale 4 Gaetano Larganà 4 Enza La Manna 4 Massimo Madonia 5 Alessandro Tedde 5 Francesco Santaniello 6 Giuseppe Vespasiani 7 Stefano Zaganelli 8 Salvatore Arnone 8 Nicola Cruciano 9 Maurizio Carrino 10 Francesco Persico 10
Carlo Terrone 11 Rita Malinaric 11
Andrea Minervini 12
Marco Carini 12
Giorgio Ivan Russo 1- 1 University of Catania, Catania, Italy
- 2 Mediterranean Institute of Oncology (IOM), Viagrande, Italy
- 3 University of Messina, Messina, Sicilia, Italy
- 4 Urology ravenna, Ravenna, Italy
- 5 University of Sassari, Sassari, Sardegna, Italy
- 6 Urology Unit Ancona, Ancona, Italy
- 7 Urology Unit, Roma, Roma, Italy
- 8 Urology Unit Lugo, Lugo di Romagna, Italy
- 9 Urology Unit Maria Vittoria Hospital, Torino, Italy
- 10 Urology Unit Cardarelli, Naples, Italy
- 11 University of Genoa, Genoa, Liguria, Italy
- 12 University of Florence, Florence, Tuscany, Italy
Introduction. Historically, medical therapy of BPH has had its foundations in alpha-blockers in monotherapy or in combination with 5 alpha reductase inhibitors (5-ARIs); in particular, two important trials (COMBAT and MTOPS) have demonstrated the pivotal role of combination therapy instead of monotherapy and have individuated which patients are most likely to benefit from alpha-blockers, 5-ARIs, or their combination. However different side effects of these drugs, such erectile dysfunction, ejaculatory disorders, loss of libido, could affect the adherence to treatment. In fact, SeR-Se-Ly would work by blocking 5-alpha reductase and the binding between the dihydrotestosterone and the androgen receptor, antagonizing the a1-adrenergic receptor, and preventing cell proliferation and the production of COX-2 and 5-leukotrienes. Prior randomized controlled trials confirmed the use of alphablockers in conjunction with Lipidic Extract (LE) of Serenoa Repens (SeR), specifically compounds containing both Selenium (Se) and Lycopene (Ly). Based on these premises, the aim of this Italian multicenter case-control prospective non-randomized study is to compare the therapy with SeR-Se-Ly alone versus Dutasteride alone against BPH, in order
Keywords: BPH, Serenoa repens, luts, Prostate, 5ARI
Received: 22 Jan 2025; Accepted: 31 Mar 2025.
Copyright: © 2025 Morgia, Lo Giudice, Cimino, Reale, Larganà, La Manna, Madonia, Tedde, Santaniello, Vespasiani, Zaganelli, Arnone, Cruciano, Carrino, Persico, Terrone, Malinaric, Minervini, Carini and Russo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Giuseppe Morgia, University of Catania, Catania, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.